Intensity therapeutics ipo
WebIn 2024, the Company executed a clinical collaboration agreement with Bristol Myers Squibb (BMS) to evaluate the combination of the Company’s lead product, INT230-6, with BMS’s anti-CTLA-4 antibody, Yervoy® (ipilimumab), in patients with advanced sarcoma, breast, and liver cancers. The cohorts are open to enrollment. Web26 rows · Intensity Therapeutics’ new IPO terms, as of Sept. 19, 2024, are: 2.22 million shares ...
Intensity therapeutics ipo
Did you know?
WebOct 18, 2024 · Intensity Therapeutics, Inc (NASDAQ: INTS) IPO will take place October, 19 on the NASDAQ exchange under the ticker INTS. The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on April 17, 2024. Intensity Therapeutics, Inc is a clinical-stage biotechnology company ... WebINTS Complete Intensity Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
WebCompany profile for Intensity Therapeutics, Inc. (INTS) with a description, list of executives, contact details and other key facts. ... Intensity Therapeutics will go public soon, but the exact IPO date is still unknown. IPO Price. $4.50. Shares Offered. 1,777,778. Deal Size. $8.00M. Overview; WebNov 9, 2024 · Intensity Therapeutics, a Phase 2 biotech developing intratumoral injection therapies for cancer, postponed its IPO on Wednesday. It had most recently filed in September to raise $10 million by offering 2.2 million shares at a price range of $4 to $5.
WebIntensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. WebDec 10, 2024 · Intensity Therapeutics is offering 2.1 million shares of its common stock in the IPO. The expected price range for the IPO is US$6-US$8 per share. Intensity Therapeutics has released a positive report for its lead proprietary investigational product candidate INT230-6.
WebOct 30, 2024 · Intensity Therapeutics has created an intratumoral therapy for killing solid tumors that also activates systemic immunity. ... (IPO) of $17.25 million worth of its common stock, and has applied to ...
WebApr 14, 2024 · February 14, 2024 finance.yahoo.com Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2024 February 14, 2024 … gregg\u0027s blue mistflowerWebOct 23, 2024 · Website: Intensity Therapeutics – A Novel Drug Approach to Kill Tumors & Activate Immune Response Possible Pricing from IPOs from Past Weeks Beamr (BMR) Beamr Beamr (BMR), an Israeli video encoding and image optimization software provider, plans to raise $15 million at a $73 million market cap. greggs uk share price today liveWebApr 20, 2024 · Intensity Therapeutics, a Phase 1/2 biotech developing intratumoral injection therapies for cancer, filed a new blank prospectus with the SEC on Wednesday, with plans to raise $17 million. The company had most recently planned to raise $15 million by offering 2.1 million shares at a price range of $6 to $8. gregg\u0027s cycles seattleWebSep 30, 2024 · Intensity Therapeutics, Inc. has completed an IPO in the amount of $8.1 million. MarketScreener Homepage Equities United States Nasdaq Intensity Therapeutics, Inc. News Summary INTS US45828J1034 INTENSITY THERAPEUTICS, INC. (INTS) Add to my list Summary Quotes News Company Financials Funds Summary Most relevant All … gregg\u0027s restaurants and pub warwick riWebNov 6, 2024 · Oncology biotech Intensity Therapeutics (INTS) plans to raise $10 million at an $82 million market cap. Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. greggs victoriaWebNov 12, 2024 · Intensity Therapeutics, a Phase 1 biotech developing intratumoral injection therapies for cancer, announced terms for its IPO on Friday. The Westport, CT-based company plans to raise $15 million by offering 1.5 million shares at a … gregg\\u0027s restaurant north kingstown riWebApr 20, 2024 · Intensity Therapeutics, a Phase 1/2 biotech developing intratumoral injection therapies for cancer, filed a new blank prospectus with the SEC on Wednesday, with plans to raise $17 million. The company had most recently planned to raise $15 million by offering 2.1 million shares at a price range of $6 to $8. gregg township pa federal prison